Supernus Pharmaceuticals, Inc.
NASDAQ:SUPNDrug Manufacturers - Specialty & Generic
+$0.51 today
- Market cap
- $6.02B
- Beta
- 0.54
- P/E (TTM)
- -87.6
- EPS (TTM)
- -$0.50
Volume 2.71M
Average 0.64M
SUPN Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Supernus Pharmaceuticals, Inc.NASDAQ: SUPN
Operating Income · Q2 FY2026 · quarter ended Jun 2026
Operating income turns negative
Q2 FY2026 operating income was -$57.96M, compared with $12.14M a year earlier. Trailing-twelve-month operating income was -$111.81M.
Context
- Operating income amounted to 5.1% of revenue in FY2025, down 7.2 pp from a year earlier.
- Operating income increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 1 analysts of $624.82M (+1794.9%) for the fiscal year ending Dec 2026, a step up from the -145.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$57.96M-679.0% QoQ
- Last fiscal yearDec 2025
- -$36.86M-145.1% YoY
- LTMJun 2026
- -$111.81M-274.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -577.4% | +421.0% | +998.4 pp |
| 1 year | -145.1% | +1794.9% | +1940.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (36.86M) USD
- Year-over-year change
- -145.1%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (36.86M) | -145.1% |
| FY2024 | 2024-12-31 | 81.67M | +1649.9% |
| FY2023 | 2023-12-31 | (5.27M) | -111.4% |
| FY2022 | 2022-12-31 | 46.12M | -46.4% |
| FY2021 | 2021-12-31 | 86.03M | — |
Operating Income vs competitors
How SUPN compares with its peers on the latest reported figures
- SUPN's LTM Jun 2026 operating income of -$111.81M is the lowest of the 3 companies compared; the peer median is $127.07M.
- Its year-over-year change of -274.3% is the lowest of 3, against a peer median of -24.2%.
- Operating income amounts to 13.5% of revenue for SUPN, versus a peer median of 13.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $189.91M | +33.6% | +77.7% | 23.8% | |
| LTM Sep 2026 | $64.23M | -82.1% | — | 3.7% | |
| LTM Jun 2026 | -$111.81M | -274.3% | — | 13.5% | |
| Peer median (excluding SUPN) | $127.07M | -24.2% | +77.7% | 13.8% | |
Competitors are the stored peer set for SUPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 579.78M | 667.24M | 607.52M | 661.82M | 718.95M |
| Cost of Revenue | 75.06M | 87.22M | 83.78M | 77.91M | 74.56M |
| Gross Profit | 504.71M | 580.02M | 523.74M | 583.91M | 644.39M |
| Gross Margin | 87.1% | 86.9% | 86.2% | 88.2% | 89.6% |
| Research & Development | 90.47M | 74.55M | 91.59M | 108.8M | 106.24M |
| Selling, General & Admin | 304.76M | 377.22M | 336.36M | 335.78M | 485.56M |
| Operating Expenses | 418.69M | 533.89M | 529.01M | 502.25M | 681.25M |
| Depreciation & Amortization | 32.6M | 85.54M | 84.86M | 80.41M | 91.56M |
| EBITDA | 129.19M | 153.36M | 90.04M | 178.28M | 42.53M |
| EBITDA Margin | 22.3% | 23.0% | 14.8% | 26.9% | 5.9% |
| Operating Income | 86.03M | 46.12M | (5.27M) | 81.67M | (36.86M) |
| Operating Margin | 14.8% | 6.9% | -0.9% | 12.3% | -5.1% |
| Interest Income | 10.57M | 21.69M | 10.45M | 16.2M | 13.25M |
| Interest Expense | 23.42M | 7.07M | 2.42M | 0 | 0 |
| Other Income / Expenses | (12.85M) | 14.62M | 8.04M | 16.2M | (12.17M) |
| Income Before Tax | 73.18M | 60.74M | 2.77M | 97.87M | (49.03M) |
| Pre-Tax Margin | 12.6% | 9.1% | 0.5% | 14.8% | -6.8% |
| Income Tax Expense | 19.75M | 32K | 1.45M | 24.01M | (10.48M) |
| Net Income | 53.42M | 60.71M | 1.32M | 73.87M | (38.55M) |
| Net Margin | 9.2% | 9.1% | 0.2% | 11.2% | -5.4% |
| EPS (Basic) | 1.01 | 1.13 | 0.02 | 1.34 | (0.68) |
| EPS (Diluted) | 0.98 | 1.04 | 0.02 | 1.32 | (0.68) |
| Weighted Avg Shares | 53.1M | 53.67M | 54.54M | 55.1M | 56.45M |
| Weighted Avg Shares (Diluted) | 54.36M | 61.68M | 55.51M | 55.96M | 56.45M |
Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
Intrinsic Alpha fair value
Locked
Current Price
$28.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.